M. Eynatten

发表

Recurrent deep venous thrombosis caused by congenital interruption of the inferior vena cava and heterozygous factor V Leiden mutation

P. Nawroth, P. Nawroth, K. Dugi, 2002, Journal of internal medicine.

LB005KIDNEY IMPLICATIONS OF THE INITIAL EGFR RESPONSE TO SGLT2 INHIBITION WITH EMPAGLIFLOZIN: THE ‘EGFR DIP’ IN EMPA-REG OUTCOME

B. Zinman, G. Bakris, C. Wanner, 2020 .

Urinary n-acetyl-beta-d-glucosaminidase Excretion: an Indicator of Neuropathy in Type 2 Diabetes

P. Nawroth, A. Bierhaus, P. Nawroth, 2013, Experimental and Clinical Endocrinology & Diabetes (Barth).

Efficacy and safety of linagliptin according to patient baseline characteristics: A pooled analysis of three phase 3 trials.

S. Del Prato, S. Patel, M. von Eynatten, 2016, Nutrition, metabolism, and cardiovascular diseases : NMCD.

Safety and efficacy of the dipeptidyl peptidase‐4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years

H. Woerle, A. Barnett, G. Schernthaner, 2014, Diabetes, obesity & metabolism.

Improved glucose control with reduced hypoglycaemic risk when linagliptin is added to basal insulin in elderly patients with type 2 diabetes

R. Henry, S. Inzucchi, H. Woerle, 2015, Diabetes, obesity & metabolism.

Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study

H. Woerle, H. Woerle, M. von Eynatten, 2013, International journal of clinical practice.

Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double‐blind, placebo‐controlled study

H. Woerle, T. Haak, T. Meinicke, 2012, Diabetes, obesity & metabolism.

Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus

H. Woerle, A. Barnett, G. Schernthaner, 2012, Diabetes, obesity & metabolism.

Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator‐controlled, double‐blind study

R. Kawamori, H. Watada, E. Araki, 2012, Diabetes, obesity & metabolism.

Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment

D. Owens, M. Taskinen, P. Groop, 2014, Diabetes, obesity & metabolism.

Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2‐year trial

J. Rosenstock, H. Woerle, B. Gallwitz, 2015, Diabetes, obesity & metabolism.